SUTUREGARD is on a mission to close more wounds simply and safely

Company Overview

Founded in 2015 and based in Portland, Oregon, SUTUREGARD™ Medical, Inc. is a privately held medical device firm with patented technology that allows surgeons to perform simple closures of high-tension wounds through rapid intraoperative tissue expansion. For skin cancer surgeons (Mohs Surgeons), SUTUREGARD’s initial target market, the SUTUREGARD™ device allows closure of wounds using tissue expansion instead of relying on flaps, grafts, or second intent healing. This is particularly useful for scalp and lower leg closures. For some skin cancer surgeons, this will add greater efficiency to their day. For other skin cancer surgeons, this will retain closures in their practice that they would have otherwise sent to other specialists.

The Company founders — a Corvallis, Oregon-based skin cancer (Moh’s) surgeon and his Ph.D. nurse business partner — designed the SUTUREGARD device. The Company invested three years conducting bench research, pre-clinical studies, and customer discovery prior to completion of a successful human use study in 2018.

“SUTUREGARD Medical launched the SUTUREGARD device in November, 2018 at the Fundamentals of Mohs Surgery Conference and the product was enthusiastically received by surgeons.”   Dan Ladizinsky, MD, CEO of SUTUREGARD Medical.

Don Urbanowicz of Urbanowicz Consulting interviews John Pracyk, MD of DePuy Synthes, Adam Wollowick, MD of Stryker Spine, and Bob Kinsella of Kinsella Group regarding trends and transactions in the spine market in a pre-NASS panel discussion entitled “From the Operating Room to the OEM.”

Capital One, BioMedGPS and Kinsella Group sponsored a panel discussion prior to the 2017 NASS meeting covering a variety of topics. The discussion, featured in the excerpt below, focuses on “From the Operating Room to the OEM” with John Pracyk, MD, PhD, MBA, FAANS, FACS, Spine Franchise Medical Leader at DePuy Synthes; Adam Wollowick, MD, MBA, Senior Director of Business Development at Stryker Spine; Bob Kinsella, President of Kinsella Group; and Don Urbanowicz, Principal of Urbanowicz Consulting (Moderator).

SmartTRAK is excited to be attending NASS - the North American Spine Society meeting on Oct 25-28, 2017 at the Orange County Convention Center in Orlando, Florida.

Don Urbanowicz, Principal, Urbanowicz Consulting and COO of SmartTRAK and Michelle Calderon, Account Manager for Orthopedics  are representing BioMedGPS SmartTRAK at the conference.

Interview with Hal Mathews, MD of Paradigm Spine, Chris Lyons of Medtronic Spine & Biologics and Don Urbanowicz of Urbanowicz Consulting.

On October 25, 2016, Capital One, BioMedGPS and Kinsella Group sponsored a panel discussion prior to NASS 2016. Multiple panel members participated in the event which covered a variety of topics. The discussion featured in the excerpt below focuses on “Insights And Perspective: Medtronic and Paradigm Spine” with Hal Mathews, M.D., MBA – Executive Vice President and Chief Medical Officer for Paradigm Spine, Chris Lyons – Director of Global Business Development for Medtronic Spine & Biologics and Don Urbanowicz of Urbanowicz Consulting.